Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Recurrence 1Breast Cancer Metastatic 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × margetuximab × Clear all
NCT04425018 2025-11-18

MARGOT

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
174 enrolled 19 charts
Breast

Breast Neoplasms

NCT01828021 2025-03-13

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

MacroGenics

Phase 2 Completed
25 enrolled 8 charts
Breast

Breast Neoplasms, Recurrence

NCT05227131 2022-07-11

MARGARET

MedSIR

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡